Astrazeneca (AZN) Minority Interest (2009 - 2026)

Astrazeneca has reported Minority Interest for 18 years, with the latest figure at $75.0 million in Q2 2026.

• On a quarterly basis, Minority Interest fell 17.58% year-over-year to $75.0 million in Q2 2026; TTM through Jun 2026 was $75.0 million, a 17.58% decrease from a year earlier, with the FY2025 full-year figure at $52.0 million, down 38.82% from the prior year.
• Minority Interest was $75.0 million for Q2 2026 at Astrazeneca, up from $51.0 million in the prior quarter.
• The five-year high for Minority Interest was $92.0 million in Q1 2025, with the low at $19.0 million in Q1 2022.
• Average Minority Interest over 5 years is $51.6 million, with a median of $51.5 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Minority Interest tumbled 88.1% in 2022, then jumped 269.57% in 2024.
• Over 5 years, Minority Interest stood at $21.0 million in 2022, then increased by 9.52% to $23.0 million in 2023, then surged by 269.57% to $85.0 million in 2024, then sank by 38.82% to $52.0 million in 2025, then surged by 44.23% to $75.0 million in 2026.
• The last three Minority Interest figures came in at $75.0 million (Q2 2026), $51.0 million (Q1 2026), and $52.0 million (Q4 2025), per Business Quant data.